CrossRef 75. Suzuki K, Matusubara H: Recent advances in p53 research and cancer treatment. J Biomed Biotech 2011, 2011:978312. 76. John Nemunaitis, PI3K Inhibitor Library Ian Ganly, Fadlo Khuri, James Arseneau, Joseph Kuhn, Todd McCarty, Stephen Landers, Phillip Maples, Larry Rome, Britta Randlev, Tony Reid, Sam Kaye, David Kirn: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000, 60:6359. 77. Boeckler FM,

Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR: Targeted rescue of a destabilised mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008,105(30):10360–10365.PubMedCrossRef 78. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht A: Characterisation of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002,21(14):2119–2129.PubMedCrossRef 79. Shangary S, Wang S: Mocetinostat cell line Small-molecule inhibitors

of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2008, 49:223–241.CrossRef 80. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang : Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumours and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008,105(10):3933–3938.PubMedCrossRef 81. Lain

S, PXD101 manufacturer Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ: Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008,13(5):454–463.PubMedCrossRef 82. Kuball J, Schuler M, Antunes Ferreira E, Herr W, Neumann M, Obenauer-Kutner L, Westreich L, Huber C, Wölfel T, Theobald M: Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther 2002,9(13):833–843.PubMedCrossRef 83. Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH: Vildagliptin Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004,53(7):633–641.PubMedCrossRef 84. Vermeij R, Leffers N, van der Burg SH, Melief CJ, Daemen T, Nijman HW: Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. J Biomed Biotechnol 2011, 2011:702146.PubMedCrossRef 85. Dai Y, Lawrence TS, Xu L: Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Tranl Res 2009,1(1):1–15. 86.